Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 /
G蛋白偶联受体/G蛋白
内分泌学/激素
/ SSTR / Lanreotide

兰瑞肽 /Lanreotide {[allProObj[0].p_purity_real_show]}

货号：A218062 同义名： BIM 23014;Laromustine

Lanreotide, a synthetic cyclic octapeptide, is the analogue of somatostatin that can inhibit somatostatin receptor 2 (SSTR-2).

Lanreotide 化学结构 CAS号：108736-35-2
Lanreotide 化学结构
CAS号：108736-35-2
Lanreotide 3D分子结构
CAS号：108736-35-2
Lanreotide 化学结构 CAS号：108736-35-2
Lanreotide 3D分子结构 CAS号：108736-35-2
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Lanreotide 纯度/质量文件 产品仅供科研

货号：A218062 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Cell Host Microbe, 2024. Ambeed. [ A163338 ]
• Cancer Res., 2024. Ambeed. [ A295334 ]
• J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]
• J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]
• JBC, 2024, 107935. Ambeed. [ A194396 ]
更多 >

Lanreotide 生物活性

描述 Lanreotide (LAN), a synthetic cyclic octapeptide, is the analogue of somatostatin that can inhibit somatostatin receptor 2 (SSTR-2). Because its half-life is longer than somatostatin, lanreotide can be used clinically to treat neuroendocrine tumors that secrete excessive amounts of growth hormone (acromegaly) or other active hormones or neuropeptides[3]. Lanreotide treatment promoted a Th1 cytotoxic immune-phenotype in patients with NETs (neuroendocrine tumors) originated by intestinal sites[4]. Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2[5]. Lanreotide treatment for 3 months before trans-sphenoidal surgery effectively reduced tumour size, and improved surgical cure rate, in newly diagnosed patients with acromegaly resulting from invasive pituitary macroadenoma[6].

Lanreotide 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02668172 Acromegaly Phase 4 Unknown June 2017 Netherlands ... 展开 >> Erasmus Medical Center Rotterdam, South Holland, Netherlands, 3000CA 收起 <<
NCT01677910 Carcinoid Syndrome Phase 3 Completed - -
NCT00642720 Quality of Life ... 展开 >> Acromegaly 收起 << Phase 4 Completed - -

Lanreotide 参考文献

[1]Michael M, Garcia-Carbonero R, et al. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. Oncologist. 2017 Mar;22(3):272-285.

[2]Tong H, Wei B, et al. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. Oncotarget. 2017 Feb 24.

[3]LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Lanreotide. 2017 Apr 11

[4]Sciammarella C, Luce A, Riccardi F, Mocerino C, Modica R, Berretta M, Misso G, Cossu AM, Colao A, Vitale G, Necas A, Fedacko J, Galdiero M, Correale P, Faggiano A, Caraglia M, Capasso A, Grimaldi A. Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. Front Oncol. 2020 Jul 7;10:1047

[5]Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33

[6]Li ZQ, Quan Z, Tian HL, Cheng M. Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. J Int Med Res. 2012;40(2):517-24

Lanreotide 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.91mL

0.18mL

0.09mL

4.56mL

0.91mL

0.46mL

9.12mL

1.82mL

0.91mL

Lanreotide 技术信息

CAS号108736-35-2
分子式C54H69N11O10S2
分子量 1096.323
别名 BIM 23014;Laromustine;Lanreotidum;ITM-014T;ITM-014;Dermopeptin;BM 23014;BIM 23014C;Angiopeptin
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Sealed in dry,Store in freezer, under -20°C
溶解度
动物实验配方

Tags: Lanreotide | 108736-35-2 | BIM 23014 | BIM23014 | BIM-23014 | Peptides | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Lanreotide 纯度/质量文件 | Lanreotide 生物活性 | Lanreotide 临床数据 | Lanreotide 参考文献 | Lanreotide 实验方案 | Lanreotide 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z